KalVista Pharmaceuticals (KALV) Cash & Current Investments (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Cash & Current Investments of $191.5 million in Q3 2025, down 13.21% quarter-over-quarter from $220.6 million in Q2 2025, and up 9.87% year-over-year from $174.3 million in Q3 2024.
KalVista Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $191.5 million for Q3 2025.
- In Q3 2025, Cash & Current Investments rose 9.87% year-over-year to $191.5 million; the TTM figure through Jul 2025 stood at $191.5 million (up 9.87% YoY), while the FY2025 annual figure was $220.6 million, up 4.86% from the prior year.
- Cash & Current Investments came in at $191.5 million for Q3 2025 at KalVista Pharmaceuticals, down from $220.6 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $268.3 million in Q4 2024 to a low of $50.3 million in Q1 2021.
- A 5-year average of $167.8 million and a median of $171.7 million in 2023 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments soared 287.17% in 2022 and tumbled 55.97% in 2024, its largest moves.
- KalVista Pharmaceuticals' Cash & Current Investments stood at $209.8 million in 2021, then slumped by 41.72% to $122.3 million in 2022, then dropped by 15.62% to $103.2 million in 2023, then soared by 160.09% to $268.3 million in 2024, then declined by 28.65% to $191.5 million in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $191.5 million, $220.6 million, and $268.3 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.13 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.01 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 191.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 191.47 Mn |
| Apr 30, 2025 | 220.62 Mn |
| Dec 31, 2024 | 268.35 Mn |
| Oct 31, 2024 | 135.78 Mn |
| Jul 31, 2024 | 174.27 Mn |
| Apr 30, 2024 | 210.40 Mn |
| Jan 31, 2024 | 75.59 Mn |
| Oct 31, 2023 | 103.17 Mn |
| Jul 31, 2023 | 123.26 Mn |
| Apr 30, 2023 | 149.38 Mn |
| Jan 31, 2023 | 171.69 Mn |
| Oct 31, 2022 | 122.27 Mn |
| Jul 31, 2022 | 142.08 Mn |
| Apr 30, 2022 | 166.20 Mn |
| Jan 31, 2022 | 194.79 Mn |
| Oct 31, 2021 | 209.81 Mn |
| Jul 31, 2021 | 230.63 Mn |
| Apr 30, 2021 | 248.93 Mn |
| Jan 31, 2021 | 50.31 Mn |
| Oct 31, 2020 | 55.87 Mn |
| Jul 31, 2020 | 64.33 Mn |
| Apr 30, 2020 | 67.71 Mn |
| Jan 31, 2020 | 80.57 Mn |
| Oct 31, 2019 | 93.46 Mn |
| Jul 31, 2019 | 100.37 Mn |
| Apr 30, 2019 | 100.81 Mn |
| Jan 31, 2019 | 111.15 Mn |
| Oct 31, 2018 | 121.12 Mn |
| Jul 31, 2018 | 48.07 Mn |
| Apr 30, 2018 | 51.06 Mn |
| Jan 31, 2018 | 58.68 Mn |
| Oct 31, 2017 | 28.13 Mn |
| Jul 31, 2017 | 26.46 Mn |
| Apr 30, 2017 | 30.95 Mn |
| Jan 31, 2017 | 33.50 Mn |
| Oct 31, 2016 | 10.69 Mn |
| Jul 31, 2016 | 15.63 Mn |
| Mar 31, 2016 | 48.59 Mn |
| Dec 31, 2015 | 53.72 Mn |
| Sep 30, 2015 | 59.88 Mn |
| Jun 30, 2015 | 65.38 Mn |
| Mar 31, 2015 | 3.18 Mn |
| Dec 31, 2014 | 3.90 Mn |
| Sep 30, 2014 | 9.33 Mn |
| Jun 30, 2014 | 7.18 Mn |
| Mar 31, 2014 | 9.28 Mn |